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Abstract
The uncertainty about the real burden of causes of death (CoD) is increasingly recognized by the international health community
as a critical limitation for prioritizing effective public health measures. The minimally invasive autopsy (MIA) has shown to be a
satisfactory substitute of the complete diagnostic autopsy (CDA), the gold standard for CoD determination in low- and middle-
income countries. However, more studies are needed to confirm its adequate performance in settings with different epidemiology.
In this observational study, the CoD obtained with the MIAwere compared with the clinical diagnosis and the results of the CDA
in 61 deaths that occurred in an infectious diseases referral hospital in Manaus, Brazilian Amazon. Concordance between the
categories of diseases obtained by the three methods was evaluated by the Kappa statistic. Additionally, we evaluated discrep-
ancies between clinical and complete diagnostic autopsy diagnoses. The MIA showed a substantial concordance with the CDA
(Kappa = 0.777, 95% CI 0.608–0.946), and a perfect or almost perfect coincidence in specific diagnosis (ICD-10 code) between
MIA and CDAwas observed in 85% of the cases. In contrast, the clinical diagnosis showed a fair concordance with the CDA
(Kappa = 0.311, 95% CI 0.071–0.552). Major clinico-pathological discrepancies were identified in 49% of cases. In conclusion,
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the MIA showed a substantial performance for CoD identification. Clinico-pathological discrepancies remain high and justify the
need for post-mortem studies, even in referral hospitals. The MIA is a robust substitute of the CDA for CoD surveillance and
quality improvement of clinical practice in low- and middle-income settings.
Keywords Cause of death . Minimally invasive autopsy . Complete autopsy . Infectious diseases . Clinico-pathological
discrepancies
Introduction
The uncertainty about the real burden of causes of death
(CoD) is increasingly recognized by the international
health community and the funding agencies as a critical
limitation for prioritizing effective public health measures
[1]. The complete diagnostic autopsy (CDA) is the gold
standard to determine the CoD, but despite its benefits,
the autopsy rates are declining worldwide [2–5]. The rea-
sons are multiple and include the invasive nature of the
procedure, which hampers its acceptability among next-
of-kin and physicians, as well as the time spent by the
pathologists and the high costs of the procedure [6, 7].
An additional reason is the perception of the clinicians
that in this era of high-tech imaging exams and accurate
laboratory tests, autopsies are no longer necessary [6].
However, major discrepancies between the clinical diag-
nosis and the final autopsy diagnosis are still relatively
frequent [8, 9].
In high-income countries, imaging-based methods have
been proposed as an alternative to the CDA, but the high costs
and the high level of expertise required are major drawbacks
for their implementation, particularly in low- and middle-
income countries (LMIC). Moreover, these imaging-based
methods could be insufficient for the identification of infec-
tious CoD [10], presumably more frequent in LMIC.
Therefore, innovative methods are necessary in LMIC, where
most premature deaths occur, and robust mortality data are
poor [1].
In recent years, the minimally invasive autopsy (MIA), a
simple method based on needle sampling of fluids and key
organs followed by histological and microbiological anal-
yses, has been developed and validated in all age groups,
including stillborn babies, neonates, children, and adults,
including maternal deaths [11–14] in Mozambique. The
concordance between the MIA and the CDA varies in the
different age groups, ranging from moderate to substantial,
and is particularly high for infectious diseases [11–14].
However, the MIA has only been tested in Mozambique
and has not been evaluated in other LMIC with different
epidemiological backgrounds. We hereby aimed to validate
the MIA approach against the CDA and to assess the con-
cordance between the clinical diagnoses and the CDA di-
agnoses in a series of deaths from an infectious diseases
tertiary hospital in Manaus, Western Brazilian Amazon.
Materials and methods
Study setting and design
This observational study was conducted at the Fundação
de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-
HVD), a tertiary hospital, which is a national and interna-
tional referral centre for the diagnosis and treatment of
tropical diseases. The Institution is located in the munic-
ipality of Manaus, in the North East of the Amazonian
State. The city has an estimated population of 2,094,301
inhabitants, of whom the majority reside in urban and
peri-urban areas [15]. Major imaging exams and laborato-
ry tests are fully available at FMT-HVD.
Deaths of any age having occurred within the hospital
from March 2014 to February 2015 were eligible for re-
cruitment. All patients had been referred to the FMT-HVD
with the suspicion of infectious diseases. The inclusion
criteria were as follows: (1) a CDA requested by the cli-
nician as part of the medical evaluation of the patient, (2)
written informed consent to perform the autopsy given by
the relatives and (3) lapse of time between death and
autopsy procedure of less than 48 h.
The study received the approval of the Clinical Research
Ethics Committee of the Hospital Clinic of Barcelona (File
3024/9688) and the local (Manaus, Amazonas state) and
Nat ional (Brazi l ) Bioethics Commit tees (CAAE
28905514.0.0000.0005/2014).
Autopsy procedures
The MIA procedure has been described in detail elsewhere
[16]. The procedure included initial disinfection of the sur-
face of the body followed by the collection of blood and
cerebrospinal fluid (CSF), aiming to collect 20 mL of each
fluid. It included the puncture of solid organs (liver, lungs
and central nervous system [CNS]) using biopsy needles
(14G–16G) and bone marrow (using a trephine needle) for
microbiological and pathological analysis. In addition, the
heart, spleen and kidneys were sampled for pathology ex-
amination. Representative figures of the sampling in a
MIA procedure and an example of a lung core obtained
during the procedure are shown in Fig. 1.
Immediately after the MIA, the CDA was conducted by
a second pathologist not involved with the MIA and
Virchows Arch
following a standardized protocol [17]. Histological and
microbiological analyses were conducted in samples from
the same viscera collected in the MIA and from any
grossly identified lesions.
Histological and microbiological analyses
A team of two pathologists (P.C., J.O.) and two microbiol-
ogists (J.C.H., M.J.M.) analysed the MIA samples blindly
to any clinical information. All the samples were stained
with haematoxylin and eosin and ancillary histochemical
and/or immunohis tochemical s ta ins i f required.
Microbiological methods have been reported in detail else-
where [18]. In brief, universal screening was performed for
all cases, which included detection of Plasmodium
falciparum and Plasmodium vivax by PCR, detection of
antibodies against HIV-1/2 and bacterial/fungal cultures
of CSF, blood, lungs, liver and CNS.
Additional microbiological screening applied to all HIV-
positive cases included real-time PCR in CSF and CNS sam-
ples for Toxoplasma gondii,Mycobacterium tuberculosis, and
Cryptococcus spp. and in lung samples for Pneumocystis
jirovecii, Cryptococcus spp. andMycobacterium tuberculosis.
Other microorganisms were tested depending on the histolog-
ical findings of the MIA or the CDA (e.g. Leishmania spp.,
Histoplasma capsulatum) [19, 20].
The pathology team in Manaus (A.P., M.F., L.F.) analysed
the CDA samples following the same approach used for the
analysis of the MIA samples, with the only exception that
CDA tissues were not routinely cultured.
Determination of the CoD
Once all the analyses of the MIA samples had been complet-
ed, a panel composed of a pathologist, a microbiologist and an
internist evaluated all the data and assigned the MIA diagno-
sis. Details of the methodology for CoD determination have
been described elsewhere [11]. Briefly, theMIA findings were
used to assign the immediate condition leading to death. For
the sake of the blind comparisonMIA-CDA, no clinical infor-
mation was used for the MIA diagnosis assignment, even if
this could potentially result in a poorer concordance. A chain
of conditions (up to four) was established following the most
probable chronological sequence of events leading to death
[21]. Fundamental diseases contributing to the death were
classified as underlying conditions (e.g. HIV infection). In
all cases, the immediate CoD and not the underlying disease
was considered as the main CoD (e.g. disseminated histoplas-
mosis in an HIV-infected patient). Other conditions or con-
comitant infections unrelated to the chain of events were con-
sidered as other significant conditions.
The team from Manaus, which included three pathologists
and an internist (A.P., M.F., L.F., M.L.), evaluated the data
from the CDA and assigned the final CDA diagnosis using
the same methodology. The CDA diagnosis integrated all the
findings from the macroscopic, histological and microbiolog-
ical analysis together with the clinical information and was
considered the Bgold standard^ diagnosis.
All morbid conditions and any underlying diseases were
codified following the International Classification of
Diseases, tenth revision (ICD-10) [22], independently for the
MIA and the CDA diagnoses. The CoD were classified into
Fig. 1 Representative figures of
the sampling in a minimally
invasive autopsy procedure. a
Cerebrospinal fluid. b Peripheral
blood. c Liver. d Lung. e Central
nervous system biopsy. f Example
of a lung core obtained during
minimally invasive autopsy
procedure
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four major categories: (1) infectious diseases, (2) malignant
tumours, (3) other diseases (including non-infectious cardio-
vascular or pulmonary diseases) and (4) non-conclusive.
Review of the clinical charts
The available clinical information was reviewed and ab-
stracted into a standardized questionnaire by one investi-
gator from Manaus (A.P.). Up to five clinical diagnoses
previously coded in ICD-10 registered in the medical re-
cord were extracted. In this list, we assumed that diagno-
sis number 1 was the principal diagnosis, and the remain-
ing diagnoses were secondary. All CoD were divided into
the four major categories of diseases. Diagnostic discrep-
ancies were evaluated using the classification of Goldman
et al. [23] modified by Battle et al. [24] and as non-
classifiable cases [25]. Major discrepancies were classi-
fied as class I or class II. Minor discrepancies were clas-
sified as classes III and IV, as previously described [8].
Correctly diagnosed patients were classified as class V.
Class VI were non-classifiable cases.
Statistical methods
The concordance between the MIA and the gold standard
diagnosis (CDA) as well as the concordance between the clin-
ical and the gold standard diagnosis were assessed by the
Kappa statistic and interpreted as suggested by Landis and
Koch [26]. The diagnostic accuracy of the MIA to identify
the categories was evaluated as sensitivity, specificity, positive
and negative predictive values and total percentage of cases
correctly classified.
Additionally, the coincidence between the MIA and the
CDA diagnoses, as well as the coincidence between the clin-
ical and the CDA diagnoses for each case were assessed by
comparing ICD-10 codes. The ICD-10 classifies diagnoses
into nested classes of different hierarchical levels, where dis-
eases or conditions are organized in chapters, blocks, and
three character categories [21, 22]. Thus, a coincidence was
classified as perfect when the ICD-10 codes were identical in
chapter, block and three-character categories [21].
Coincidence was classified as moderate when the codes were
within the same chapter and block, but there was a discrepan-
cy in the three-character category and as low when the codes
were within the same chapter, but there was a discrepancy in
the block and three-character categories. When the MIA and
the gold standard diagnoses were in a different chapter, the
coincidence in diagnosis was classified as Bnone^.
Statistical analyses were performed using the Stata
Software (Version 15, StataCorp 2017, College Station,
TX, USA).
Results
General characteristics of the series
Coupled MIA and CDA were performed to 61 patients (39
males [64%] and 22 females [36%]). Fifty-nine of the patients
were adults; two of them were maternal deaths (one woman
who died during pregnancy and another who died during the
puerperal period). The series included two children (a female
and a male, both 13 years old). The median age of the overall
group was 34.8 (range 13.9 to 81.5 years).
Gold standard (CDA) diagnosis of CoD
A final CoDwas identified in the CDA for all cases. The CDA
classified 44/61 (72%) deaths as infectious (28 disseminated,
eight pulmonary, seven CNS, and one liver infection). Eleven
deaths (18%) were caused by malignancies (five liver cell
carcinomas, six other malignancies), and 6/61 deaths (10%)
were caused by other diseases. None of the maternal deaths
was of a direct obstetric cause (one pulmonary thromboembo-
lism complicating sickle cell anaemia and a liver cell
carcinoma).
An underlying CoD was identified in the CDA in 51/61 of
the cases (84%). Underlying diseases included HIV infection
in 37 patients (61%). All of them tested positive for HIV
antibodies (all being HIV-1). Hepatitis B virus (HBV) infec-
tion was identified in seven cases, three of them with an
HDV(Hepatitis D virus)-HBV co-infection. In three patients,
cirrhosis without aetiology was identified. One patient had
sickle cell anaemia, one HTLV(Human T-lymphotropic virus)
I-II infection and one systemic lupus erythematosus with
glomerulonephritis.
Concordance in disease categorization
between the MIA and the CDA and accuracy
of the MIA
A final cause of death was identified in the MIA in all cases.
The MIA categorization of diseases agreed with the gold stan-
dard in 55/61 (90%) of the cases and showed a substantial
concordance with the CDA categorization (Kappa = 0.780,
95% CI 0.608–0.946). Concordance in all categories was
high, with a 100% (6/6) for other diseases, 93% (41/44) for
infections and 73% (8/11) for the malignancies. From the
discrepant cases, three out of 44 infections were classified as
other diseases, and three out of eight malignancies were clas-
sified as infections.
Table 1 shows the sensitivity, specificity, the positive and
negative predictive values for the major diagnostic categories,
as well as the accuracy of the MIA diagnoses. Sensitivity and
overall accuracy of the MIAwere high for all categories, over
70% and 90%, respectively.
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Coincidence between the MIA and the gold standard
diagnoses
For the cases with no discrepancies (n = 55) between the MIA
and the CDA diagnoses, we performed an additional analysis
to evaluate the degree of coincidence (from perfect to none)
between the specific ICD-10 diagnoses. Table 2 summarizes
the coincidence in ICD-10 coding, in terms of identical chap-
ter and block, according to disease category. The coincidence
was perfect (i.e. the same specific disease, diagnosed as the
CoD) in 47 of the 55 cases (85%). For the disease categories,
this perfect level of coincidence was 67% for other diseases,
being higher for infectious diseases and malignant tumours
(over 85%, each). In the seven cases with moderate to low
coincidence, the MIA failed to determine the organ or the
microorganism (five cases of infectious diseases), the location
of the carcinoma (one case) or the precise cardiovascular dis-
ease leading to death (one case of other diseases). In one case,
the coincidence was considered none and included a pulmo-
nary thromboembolism complicating a sickle cell anaemia
crisis in which the MIA identified only a pulmonary infarct.
Other significant diseases or co-infections were identified
in 33/61 (54%) cases of the MIA and in 42/61 (69%) cases of
the CDA, being coincident between the MIA and the CDA in
28 cases (46%).
Table S1 summarizes the CDA and MIA CoD, the under-
lying conditions and any other significant conditions identi-
fied at the CDA and the MIA for each individual patient, as
well as the ICD-10 code for each diagnosis and coincidence
between the MIA and the gold standard diagnosis.
Aetiological agents and contribution of pathological
and microbiological findings in infectious CoD
In 40/44 (91%) of the infection-related deaths, the aetiological
agent was identified in the CDA. In the group of disseminated
infections, seven patients had a milliary tuberculosis (6/7 HIV-
positive), six had a disseminated histoplasmosis (all of them
HIV-positive), five had a bacterial sepsis (three Neisseria
meningitidis, two Streptococcus pneumoniae [one of the latter
HIV-positive]), three had a disseminated cryptococcosis, three
had a toxoplasmosis and two patients disseminated cytomeg-
alovirus disease (all of them HIV-positive). Finally, one pa-
tient had disseminated leishmaniasis and one histological find-
ings of haemorrhagic viral disease, although the agent was not
identified after testing for dengue, yellow fever, leptospirosis
and hantaviruses. The pulmonary infections included one tu-
berculosis, one pneumocystosis and two cases of
cytomegaloviral pneumonia (all in HIV-positive patients);
we also diagnosed two patients with pneumonia and one case
with organizing pneumonia, but no agent was identified. The
CNS infections included three toxoplasmosis, two cryptococ-
cosis (all in HIV-positive patients) and two bacterial meningi-
tis (one caused by N. meningitidis and one by Klebsiella
pneumoniae).
Table 1 Sensitivity, specificity, positive and negative predictive value (PPVand NPV) and accuracy of the MIA for the different diagnostic categories.
Figures are percentages and 95% confidence intervals
Cause of death Number Sensitivity Specificity PPV NPV Correctly classified
Infectious diseases 44 93 (85,99) 82 (57,96) 93 (82,99) 82 (57,96) 90 (80,97)
Malignant tumours 11 73 (39,94) 100 (93,100) 100 (63,100) 94 (84,99) 95 (86,99)
Other diseases 6 100 (54,100) 95 (85,100) 67 (30,93) 100 (93,100) 95 (86,99)
Kappa (Std. Err.) 0.777—Substantial. 95% CI 0.608–0.946
MIA minimally invasive autopsy
Table 2 Diagnostic coincidence
within the 55 cases with
concordant diagnosis between the
MIA and the CDA
Disease group Coincidence in diagnosis (MIA vs. CDA)
Perfect/almost perfect Moderate or low None
n % (95% CI) N % (95% CI) n % (95% CI)
Overall (n = 55) 48 87 (66–88) 6 11 (4–20) 1* 4 (0–8)
Infectious diseases (n = 41) 37 90 (47–72) 4 10 (2–16) 0 0 (0–6)**
Malignant tumours (n = 8) 7 87 (5–22) 1 12 (0–9) 0 0 (0–6)**
Other diseases (n = 6) 4 67 (2–16) 1 17 (0–9) 1 17 (0–9)
MIA minimally invasive autopsy, CDA complete diagnostic autopsy, CI confidence interval
*The case in which the coincidence was considered Bnone^ is a sickle cell anaemia crisis that the MIA diagnosed
as a pulmonary infarct. **One-sided, 97.5% Confidence interval
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The same microorganism identified in the gold standard
CDA was identified in the MIA in 35 out of the 40 cases
(87%). Table 3 shows the aetiological agents identified in
the CDA and in the MIA.
Among the 44 infection-related deaths, the pathological
findings alone were sufficient for the cause of death diagnosis
in 12 cases (27%) of the MIA and in 5 cases (11%) of the
CDA. In 23 cases (52%) of the MIA and in 39 (89%) cases of
the CDA, the pathological and the microbiological findings
contributed equally, with microbiology providing information
on the aetiological agent. Finally, in 9 cases of theMIA (21%),
the pathological findings were non-conclusive and the diag-
nosis was based on the microbiological analysis.
Clinico-pathological discrepancies
The clinical categorization of disease showed a fair concor-
dance with the CDA categorization (Kappa = 0.311, 95% CI
0.071–0.552). The sensitivity of the clinical diagnosis was
93% for infectious diseases (95% CI 81–93%), 67% for other
diseases (95% CI 22–96%) and 0% for malignant tumours
(95% CI 0–28%).
Overall, a diagnostic discrepancy was determined in 31/61
(51%) of the cases. A major diagnostic discrepancy was de-
tected in 30 (49%) of deaths: 25 (41%) were classified as class
I, and five (8%) as class II. A minor diagnostic discrepancy
(class III) was identified in one case. In 30 cases (49%), there
was complete agreement between the clinical and the autopsy
diagnoses (class V). Twenty-one of the 30 major discordances
(70%), occurred in infections, six (20%) in malignancies and
three (10%) in other diseases. No statistical differences in
terms of percentage of major errors were observed between
the main diagnostic categories (p = 0.142). No association was
observed between demographic data, clinical symptoms at
admission and biochemical parameters and type of clinico-
pathological discrepancies.
Discussion
To our knowledge, this is the first study reporting the validity
of a standardized MIA for CoD determination and including
the evaluation of the clinico-pathological discrepancies in the
Brazilian Amazon. The validation study shows a substantial
degree of concordance (90%; kappa value of 0.78) between
the MIA and the gold standard diagnoses. The concordance
was remarkably high in all disease categories, particularly for
infectious diseases. These results are consistent with the re-
ported concordance in a series of adults in Mozambique [11]
and show that the MIA can be an adequate alternative in
LMIC settings, where mortality statistics are poor.
Infectious diseases, representing over 70% of all deaths,
and HIV infection (61% of all cases) were as prevalent as in
our previous study in Mozambique [11]. These infections in-
clude endemic diseases such as histoplasmosis and leishman-
iasis, as well as microorganisms such as N. meningitidis that
were not identified in previous validation studies [11, 13, 14].
Importantly, in 87% of the cases, the aetiological microorgan-
ism was identified in the MIA. Interestingly, all five missed
aetiological agents, not identified at MIA and detected with
molecular methods in the CDA-obtained tissues, were CNS
infections. In three cases, this was due to the absence of men-
ingeal membranes in the MIA sample (two meningitis), and in
two cases, the histological lesion and the microorganism were
absent in MIA sample (two toxoplasmosis). These findings
also indicate that the CSF collected, during MIA, cannot be
sufficient on its own to identify infectious agent affecting the
CNS. Future MIA protocols may benefit from an increase in
the number of CNS samples in order to increase the yield of
the microbiological and histological results in meningeal
infections.
Similar to other settings, M. tuberculosis was the most fre-
quent fatal opportunistic infection among HIV-positive pa-
tients inManaus.Cryptococcus spp. was also a frequent cause
of death [11, 27]. In keeping with other studies in Latin
America [28], histoplasmosis, an endemic fungal infection,
was the second most frequent infectious disease identified as
CoD in the HIV-positive patients from our series. In a previous
autopsy study conducted in the same setting and including
HIV patients from 1996 to 2003, tuberculosis (28%) and his-
toplasmosis (17%) were also the two most frequent causes of
death [29]. These results are similar to other studies in Latin
America, including Brazil, reporting high incidence and mor-
tality of histoplasmosis especially in HIV-positive patients
[30–32]. The high frequency of histoplasmosis in this area
indicates that this infection needs to be considered as part of
the differential diagnosis early during clinical management of
HIV-positive patients.
Bacterial pneumonia was an infrequent CoD in the present
series in HIV-positive patients, which contrasts with previous
reports [29, 33]. These results may reflect an improvement in
the management of bacterial infections in HIV-positive pa-
tients [29]. Finally, blood samples obtained during MIA,
allowed us to identify all HBV infections (seven cases), which
in three cases had an associated HDV co-infection. In addi-
tion, an HTLV I-II co-infection was also identified.
Hepatocellular carcinoma was the most frequent malignan-
cy in this series; all were diagnosed in HIV negative patients.
Four out of the five hepatocellular carcinomas identified were
associated with HBV infection. Thus, although HCVinfection
is now the most frequent risk factor associated with HCC in
South America, including Brazil [34, 35], HBV infection re-
mains an important risk factor for HCC in some regions, in-
cluding the study area. The high accuracy of MIA to detect
malignant tumours is consistent with previous data [11].
However, in three patients, a malignant tumour identified in
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the CDA was not diagnosed in the MIA. All these tumours
missed at MIAwere localized tumours, being out of the target
regions of the MIA (hepatocarcinoma, one large B cell lym-
phoma and one gastric adenocarcinoma).
Clinico-pathological discrepancies were identified in 51%
of the cases (31/61), with most of the discrepancies being
major errors (30 cases; 49% of the overall series).
Importantly, in most patients (41%), a change in the clinical
management could have significantly modified the prognosis
(type I errors). The percentage of discrepancies observed in
this series is similar to the data of tertiary hospital of
Mozambique and is higher than in most studies based on
unselected hospital patients [18, 23–25].
The main limitation of our study is that it was conducted
in a referral tertiary care centre focused on infectious dis-
eases, in a cohort of cases with a high HIV prevalence, not
representative of the population. This could limit the ex-
trapolation of the findings to other health facilities and to
high-income countries, where HIV and infections may be
less prevalent and cardiovascular diseases and malignant
neoplasms are frequent causes of death. However, the
present study was conducted in a completely different geo-
graphic area compared to our previous studies, conducted
in sub-Saharan Africa [11, 12, 14], indicating that MIA
may provide robust mortality data irrespectively of the
region.
In conclusion, in this series of adult deaths from the
Brazilian Amazon, the MIA showed a substantial perfor-
mance for CoD determination. The results confirm that
the MIA is a valid tool, comparable to the gold standard
methodology, particularly for infectious diseases, and that
it can be reliably considered an adequate proxy for the
CDA for CoD surveillance and quality improvement of
clinical practice. The high accuracy of the MIA to detect
infectious diseases indicates that the procedure has a po-
tential use to detect infectious diseases outbreaks and
emerging diseases in sentinel sites. Major clinico-
pathological discrepancies remain significantly high
(41%), even in a referral hospital with adequate diagnostic
resources and specialized physicians, as to justify the need
for post-mortem procedures, which may help to improve
clinical practice in LMIC.
Table 3 List of aetiological agents identified in the complete diagnostic autopsy, the minimally invasive autopsy and in both methods, expressed in
number of cases
Aetiological agents Complete diagnostic
autopsy (CDA, gold standard)
Minimally invasive autopsy (MIA) Microorganism identified by both
methods (MIA and CDA)
Disseminated infections 27 27 27
Mycobacterium tuberculosis 7 7 7
Histoplama capsulatum 6 6 6
Cryptococcus spp. 3 3 3
Toxoplasma gondii 3 3 3
Neisseria meningitidis 3 3 3
Cytomegalovirus 2 2 2
Streptococcus pneumoniae 2 2 2
Leishmania spp. 1 1 1
Pulmonary infections 5 5 5
Cytomegalovirus 2 2 2
Pneumocystis jirovecii 1 1 1
Pseudomonas aeruginosa 1 1 1
Mycobacterium tuberculosis 1 1 1
Central nervous system infections 7 2 2
Toxoplasma gondii 3 1 1
Cryptococcus spp. 2 0 0
Neisseria meningitidis 1 1 1
Klebsiella pneumoniae 1 0 0
Other infections 1 1 1
Viral hepatitis A 1 1 1
Total 40 35 35
The entries that were marked in bold are the main groups of different diagnosis
*No agent was identified in three pulmonary infections and one disseminated infection
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